Search for: "U.S. v. Janssen"
Results 21 - 40
of 117
Sorted by Relevance
|
Sort by Date
17 Mar 2021, 7:14 pm
(here) When assessing the merits of the APA arguments at a summary judgment hearing last week, U.S. [read post]
24 Nov 2010, 10:57 am
The U.S. [read post]
2 Mar 2017, 7:07 am
Orr v. [read post]
20 May 2011, 8:53 am
Janssen, L.P., ___ F. [read post]
15 Jan 2010, 8:00 am
Janssen Pharmaceutica Inc., 2007 WL 2022173 (D.S.C. [read post]
1 Apr 2024, 10:58 am
Janssen Pharms., Inc. v. [read post]
23 Jun 2008, 2:54 am
Jassen, L.P. et al. v. [read post]
8 Apr 2024, 9:47 am
Hunt, 455 U.S. 478, 481 (1982). [2] Kingdomware Techs., Inc. v. [read post]
2 Jul 2014, 1:42 pm
Janssen Biotech and Centocor Biologics (Fed. [read post]
23 Jan 2018, 7:29 pm
In an ex parte reexamination of U.S. [read post]
14 Feb 2010, 4:20 pm
Cir. 2009) Eli Lilly & Co. v. [read post]
11 Aug 2011, 7:58 am
” Ortho-McNeil-Janssen Pharmaceuticals Inc. is accused of the following: Promoting Risperdal for uses that were neither approved by the U.S. [read post]
8 Jan 2009, 4:07 am
Janssen LLP, 2008 WL 5413105 (D.N.J. [read post]
24 Oct 2014, 7:56 am
Janssen Pharmaceuticals, Inc., No. 3:12-oe-40003, 2014 U.S. [read post]
23 Nov 2015, 8:00 am
The result was a $2.2 billion settlement between Janssen and the U.S. [read post]
22 Mar 2016, 6:12 am
Hoffmann-La Roche AG and Genentech Inc. | Design v Copyright in Italy | Unitary patent and double patenting | Regeneron Pharmaceuticals Inc v Kymab Ltd & Anor | IKEA in Indonesia | Eli Lilly v Janssen Sciences. [read post]
6 Oct 2010, 11:43 pm
” In applying the Caraco-Janssen decisions, the Federal Circuit ruled that Teva v. [read post]
5 Dec 2022, 6:55 am
The court granted Teva’s motion, finding the facts analogous to the Federal Circuit’s decision in Janssen Pharmaceutica, N.V. v. [read post]
5 Dec 2022, 6:55 am
The court granted Teva’s motion, finding the facts analogous to the Federal Circuit’s decision in Janssen Pharmaceutica, N.V. v. [read post]
5 Dec 2022, 6:55 am
The court granted Teva’s motion, finding the facts analogous to the Federal Circuit’s decision in Janssen Pharmaceutica, N.V. v. [read post]
